RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and lowers the price target from $140 to $130.